Here's how tesamorelin vs sermorelin and other GHRH peptides compare: GHRH Peptide Comparison Table Property Tesamorelin Sermorelin CJC-1295 (No DAC) CJC-1295 DAC FDA Status FDA Approved (Egrifta) Previously approved, now discontinued Not approved Not approved Amino Acids 44 (modified GHRH) 29 (GHRH 1-29) 29 + modifications 29 + Drug Affinity Complex Half-Life ~26-38 minutes ~10-20 minutes ~30 minutes ~6-8 days Mechanism GHRH receptor agonist GHRH receptor agonist GHRH receptor agonist GHRH receptor agonist (extended) Clinical Trial Data Extensive (Phase 3 completed) Limited (older studies) Limited (Phase 1/2) Limited Primary Research Use Lipodystrophy, NAFLD, body composition GH deficiency research GH axis research Extended GH release research Key Differentiators Tesamorelin's advantages: Only GHRH analog with current FDA approval Extensive Phase 3 clinical trial data Documented efficacy for visceral fat reduction Well-characterized safety profile from prescription use Sermorelin note: Previously FDA-approved (1997) for pediatric growth hormone deficiency but discontinued by manufacturers no longer available as a prescription product in the US
The primary trade-off is an increased risk of minor GI or hypersensitivity side effects that, until now, havent diluted the benefits for most users
After 18 h, the cells in upper chamber were fixed in methanol and underwent crystal violet staining
Designed to help maintain mental clarity and motivation during calorie restriction
FOXO1 loss might contribute to the disturbed terminal differentiation observed in osteosarcoma
No Blood Sugar or Insulin Impact (Human Data) Evidence quality: Strong (clinical confirmation) In contrast to full-length growth hormone which reliably worsens insulin sensitivity chronic AOD-9604 treatment showed no adverse effect on carbohydrate metabolism
